Citrus auraptene: A potential multifunctional therapeutic agent for nonalcoholic fatty liver disease

Annals of Hepatology

Volumn 10, Issue 4, 2011, Pages 575-577

  Sahebkar, Amirhossein ^a  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

AURAPTENE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRIACYLGLYCEROL;

ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTIOXIDANT ACTIVITY; CITRUS FRUIT; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; FATTY ACID OXIDATION; FATTY LIVER; HUMAN; IMMUNOMODULATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LETTER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; NEUROPROTECTION; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; RUTACEAE;

EID: 80052701554     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31530-3     Document Type: Letter

References (20)

1. Salt 2nd, WB. Nonalcoholic fatty liver disease (NAFLD): A comprehensive review. J Insur Med 2004; 36: 27-41.
2. Epifano F, Genovese S, Curini M. Auraptene: Phytochemical and pharmacological properties. In: Matsumoto T (ed.). Phytochemistry research progressed. New York: Nova Science Publishers Inc.; 2008, p.145-62.
3. Ogawa K, Kawasaki A, Yoshida T, Nesumi H, Nakano M, Ikoma Y, Yano M. Evaluation of auraptene content in citrus fruits and their products. J Agric Food Chem 2000; 48: 1763-9.
4. Curini M, Cravotto G, Epifano F, Giannone G. Chemistry and biological activity of natural and synthetic prenyloxycoumarins. Curr Med Chem 2006; 13: 199-222.
5. Genovese S, Epifano F. Auraptene: a natural biologically active compound with multiple targets. Curr Drug Targets 2011; 12: 381-6.
6. Kohno H, Suzuki R, Curini M, Epifano F, Maltese F, Gonzales SP, Tanaka T. Dietary administration with prenyloxycoumarins, auraptene and collinin, inhibits colitis-related colon carcinogenesis in mice. Int J Cancer 2006; 118: 2936-42.
7. Prince M, Li Y, Childers A, Itoh K, Yamamoto M, Kleiner HE. Comparison of citrus coumarins on carcinogen-detoxifying enzymes in Nrf2 knockout mice. Toxicol Lett 2009; 185: 180-6.
8. Murakami A, Nakamura Y, Tanaka T, Kawabata K, Takahashi D, Koshimizu K, Ohigashi H. Suppression by citrus auraptene of phorbol ester-and endotoxin-induced inflammatory responses: role of attenuation of leukocyte activation. Carcinogenesis 2000; 21: 1843-50.
9. Takeda K, Utsunomiya H, Kakiuchi S, Okuno Y, Oda K, Inada K, Tsutsumi Y, et al. Citrus auraptene reduces Helicobacter pylori colonization of glandular stomach lesions in Mongolian gerbils. J oleo Sci 2007; 56: 253-60.
10. Soltani F, Mosaffa F, Iranshahi M, Karimi G, Malekaneh M, Haghighi F, Behravan J. Auraptene from Ferula szowitsiana protects human peripheral lymphocytes against oxidative stress. Phytother Res 2010; 24: 85-9.
11. Epifano F, Molinaro G, Genovese S, Ngomba RT, Nicoletti F, Curini M. Neuroprotective effect of prenyloxycoumarins from edible vegetables. Neurosci Lett 2008; 443: 57-60.
12. Tanaka T, Sugiura H, Inaba R, Nishikawa A, Murakami A, Koshimizu K, Ohigashi H. Immunomodulatory action of citrus auraptene on macrophage functions and cytokine production of lymphocytes in female BALB/c mice. Carcinogenesis 1999; 20: 1471-6.
13. Polyzos SA, Kountouras J, Zavos C, Tsiaousi E. The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease. Diab Obes Metab 2010; 12: 365-83.
14. Kuroyanagi K, Kang MS, Goto T, Hirai S, Ohyama K, Kusudo T, Yu R, et al. Citrus auraptene acts as an agonist for PPARs and enhances adiponectin production and MCP-1 reduction in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2008; 366: 219-25.
15. Kallwitz ER, McLachlan A, Cotler SJ. Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease. World J Gastroenterol 2008; 14: 22-8.
16. Takahashi N, Kang MS, Kuroyanagi K, Goto T, Hirai S, Ohyama K, et al. Auraptene, a citrus fruit compound, regulates gene expression as a PPARα agonist in HepG2 hepatocytes. BioFactors 2008; 33: 25-32.
17. Diehl AM. Tumor necrosis factor and its potential role in insulin resistance and nonalcoholic fatty liver disease. Clin Liver Dis 2004; 8: 619-38.
18. Tanaka T, De Azevedo MBM, Durán N, Alderete JB, Epifano F, Genovese S, Tanaka M, et al. Colorectal cancer chemoprevention by 2 β-cyclodextrin inclusion compounds of auraptene and 4'-geranyloxyferulic acid. Int J Cancer 2010; 126: 830-40.
19. Murakami A, Nakamura Y, Tanaka T, Kawabata K, Takahashi D, Koshimizu K, Ohigashi H. Suppression by citrus auraptene of phorbol ester- and endotoxininduced inflammatory responses: Role of attenuation of leukocyte activation. Carcinogenesis 2000; 21: 1843-50.
20. Nagao K, Yamano N, Shirouchi B, Inoue N, Murakami S, Sasaki T, Yanagita T. Effects of Citrus Auraptene (7-Geranyloxycoumarin) on hepatic lipid metabolism in vitro and in vivo. J Agric Food Chem 2010 [Epub ahead of print] DOI: 10.1021/jf1020329.